Critical Comparison: Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) & Omeros (NASDAQ:OMER)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Volatility and Risk

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Omeros	N/A	-102.16%	64.87%

Earnings and Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and Omeros”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.46	$363.05 million	($1.41)	-19.81
Omeros	N/A	N/A	-$3.35 million	$0.70	19.59

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Omeros. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Lakefront Biotherapeutics American Depositary Shares and Omeros, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	7	0	1	2.25
Omeros	0	3	2	1	2.67

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $30.67, indicating a potential upside of 9.80%. Omeros has a consensus price target of $38.00, indicating a potential upside of 177.17%. Given Omeros’ stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Insider and Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Omeros beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 12 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.